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ABSTRACT
Objectives: Suboptimal bone health is increasingly
recognised as an important cause of morbidity.
Multiple sclerosis (MS) has been consistently
associated with an increased risk of osteoporosis and
fracture. Various fracture risk screening tools have
been developed, two of which are in routine use and a
further one is MS-specific. We set out to compare the
results obtained by these in the MS clinic population.
Design: This was a service development study. The
10-year risk estimates of any fracture and hip fracture
generated by each of the algorithms were compared.
Setting: The MS clinic at the Royal London Hospital.
Participants: 88 patients with a confirmed diagnosis
of MS.
Outcome measures: Mean 10-year overall fracture
risk and hip fracture risk were calculated using each
of the three fracture risk calculators. The number
of interventions that would be required as a result of
using each of these tools was also compared.
Results: Mean 10-year fracture risk was 4.7%, 2.3%
and 7.6% using FRAX, QFracture and the MS-specific
calculator, respectively (p<0.0001 for difference). The
agreement between risk scoring tools was poor at all
levels of fracture risk.
Conclusions: The agreement between these three
fracture risk scoring tools is poor in the MS
population. Further work is required to develop and
validate an accurate fracture risk scoring system for
use in MS.
Trial registration: This service development study
was approved by the Clinical Effectiveness Department
at Barts Health NHS Trust (project registration number
156/12).
INTRODUCTION
Suboptimal bone health is increasingly
recognised as an important cause of morbid-
ity. Recent National Institute of Clinical
Excellence (NICE) guidelines in the UK1
recommend assessing bone health using one
of two validated scoring systems, FRAX and
QFracture, in those at risk of fragility
fracture.2 3 These scores, both of which have
been generated from and validated against
large databases, allow the calculation of an
individual’s 10-year fracture risk, both in
terms of any fracture and hip fracture. NICE
guidelines currently recommend the calcula-
tion of fracture risk before proceeding to
dual x-ray absorptiometry (DXA) imaging.1
ARTICLE SUMMARY
Article focus
▪ Recent National Institute of Clinical Excellence
(NICE) guidelines in the UK recommend assessing
bone health using one of two validated scoring
systems, FRAX and QFracture, in those at risk of
fragility fracture. However, these fracture risk
scoring systems do not take into account all risks
associated with fragility fractures.
▪ Multiple sclerosis (MS) has been associated with
an increased hazard ratio of hip fracture, and
was one of the two neurological conditions sig-
nificantly associated with an increased risk of
fracture in the Global Longitudinal study of
Osteoporosis in Women (GLOW) study.
▪ This study therefore set out to compare existing
fracture risk scoring algorithms in a multiple
sclerosis clinic, in order to assess both the effect
of using each of the algorithms on further inves-
tigations and treatment, and to assess whether
the algorithms provide similar results in this
clinic population.
Key messages
▪ The agreement between fracture risk calculators
is poor, with QFracture consistently giving lower
risk estimates than FRAX.
▪ While reducing fracture risk should be a priority
to all clinicians dealing with chronic conditions
associated with an increased risk of fracture,
there must be consistency in the way in which
fracture risk is calculated. A prospective study is
urgently required in order that we can determine
the best way to predict and prevent fractures.
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However, these fracture risk scoring systems do not
take into account all risks associated with fragility frac-
tures. Multiple sclerosis (MS) has been associated with a
hazard ratio (HR) of hip fracture of 1.9–4.08,4 and was
one of the two neurological conditions signiﬁcantly asso-
ciated with an increased risk of fracture in the Global
Longitudinal study of Osteoporosis in Women (GLOW)
study (HR of any fracture in MS 1.7; 95% CI 1.2 to 2.6).5
There have been recent efforts to develop a fracture risk
calculator that takes into account the increased risk of
fracture and osteoporosis associated with MS.6 However,
this calculator has been developed from a single data-
base, the UK General Practice Database, and has not
been validated to date.
There are common factors associated with an increased
risk of developing MS and an increased fracture risk, such
as vitamin D deﬁciency and smoking. It therefore seems
likely that the increased fracture risk associated with MS
develops early in the disease.4 Indeed, it has been shown
that the lowered bone mineral density (BMD) associated
with MS develops while patients remain fully mobile.4 This
leads to problems using fracture risk assessment tools, as
the FRAX algorithm has the lower age limit set at 40 years,
while in the QFracture algorithm the lowest age is 30. The
mean age of MS diagnosis is approximately 29,7 implying
that many patients are ﬁrst seen at a relatively young age.
It has been argued that the 10-year fracture risk at
which intervention becomes cost-effective varies accord-
ing to the country in which the societal cost is mod-
elled.8 For a 50-year-old individual, the 10-year fracture
risk at which it becomes cost-effective to intervene may
be as low as 0.84% in the UK (a relative risk of osteopor-
otic fracture of 1.83 compared to the general popula-
tion, similar to that associated with MS; in the USA,
treatment at a relative risk of 1.31 is thought to be cost-
effective).8 This highlights the importance of fracture
risk screening in the MS clinic population.
Given the importance of fracture risk screening in the
population with MS and the uncertainty regarding which
risk calculator to use, we set out to compare the three frac-
ture risk calculator systems in the MS outpatient clinic
population. This study enables a direct comparison of the
fracture risk estimates generated by these three studies in
addition to examining the number of interventions that
the use of each of these calculators would result in.
METHODS
Patient selection and data collection
This service development study was approved by the
Clinical Effectiveness Department at Barts Health NHS
Trust (project registration number 156/12). One
hundred patients with clinically deﬁnite MS attending
either the MS outpatient clinic or the Neurology
Daycase Unit were assessed. Sufﬁcient data to enable full
fracture risk scoring were available on 88 patients (see
table 1 for details of data required for each fracture risk
calculator). The use of an assistive device for walking
together with details regarding MS duration and treat-
ment, previous DXA imaging, previous fragility or other
fracture, and medications used for the treatment of
reduced BMD were also recorded.
Fracture risk scoring
Ten-year risk of both ‘any fracture’ and ‘hip fracture’
were assessed using the FRAX scoring algorithm,2 the
QFracture algorithm3 and the recently proposed
MS-speciﬁc fracture risk score algorithm.6 As the FRAX
score algorithm only allows a minimum age of 40 years,
patients aged <40 were assigned an age of 40 for the
purposes of this calculation. The QFracture algorithm
allows a minimum age of 30, and so patients aged <30
were assigned an age of 30. The MS-speciﬁc fracture risk
calculator does not have a lower age cut-off. A result of
this was that patients aged <40 were assigned different
ages in at least two of the risk calculations. A subgroup
analysis was performed including only those patients
aged 40 or over, in order to assess whether the inclusion
of patients younger than the cut-off age had affected the
results.
In order to assess the number of patients who would
require DXA imaging and/or treatment, an imaging
threshold of a 10-year fracture risk for any fracture of
>5% was assigned. The treatment threshold was taken to
be a 10-year fracture risk of >7% for any fracture, and
>4% for hip fracture. The UK National Osteoporosis
Guideline Group (NOGG) has estimated that, in the
UK, pharmacological treatment is cost-effective at all
ages when the 10-year probability of major osteoporotic
fracture exceeds 7%.9 The UK NOGG recommends an
age-dependent intervention threshold, which ranges
from 1-year to 10-year fracture risk of 7.5–30% for ages
50–80 years.10 However, these ﬁgures are, if anything,
somewhat conservative as discussed above.
Statistical analysis
Statistical analysis was performed using PASW V.18.0
(SPSS). Risk score distributions were assessed for nor-
mality using a Shapiro-Wilk test, and attempts made to
normalise the data using a natural log transformation.
As it proved impossible to normalise the data, non-
parametric statistical tests were used. The absolute risk
scores generated by each fracture risk score were directly
compared using the Friedman test. Scores were then
ARTICLE SUMMARY
Strengths and limitations of this study
▪ To the best of our knowledge, this is the first study to directly
compare fracture risk scoring tools in the MS clinic population,
assessing the rate of interventions that would be indicated by
using each tool.
▪ This study is of relatively small sample size; however, it pro-
vides important pilot data to support further work in this area.
▪ The lack of longitudinal follow-up does not allow us to fully
assess the relative accuracy of each tool. Further longitudinal
prospective studies are required.
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compared between pairs of risk scoring systems using
the Wilcoxon signed-rank test.
The agreement between individual scores was assessed
using a Bland-Altman plot.11 This method allows a visual
description of the agreement between scores, in addition
to demonstrating any systematic or signiﬁcant proportional
errors between the two sets of results.11 A further analysis
was performed by putting the scores obtained into rank
order, and separating them into rank order quintiles, an
accepted technique used in the MS literature.12 13 The
agreement between quintiles was then compared using
the κ coefﬁcient. Finally, the proportion of individuals
meeting the pre-set criteria for DXA imaging and poten-
tial treatment intervention was compared using Fisher’s
exact test.
RESULTS
Subjects
Of the 100 patients recruited, 88 gave sufﬁcient informa-
tion to allow their 10-year fracture risk to be accurately cal-
culated using the three algorithms. Demographic details
of these patients are given in table 2. Mean disease dur-
ation was 7.96 years (range 0–30); 76/88 patients were
receiving disease-modifying treatment (see table 2 for
more information). Of the 100 patients, 42 used a walking
aid; of whom 8 required bilateral assistance and 4 used a
wheelchair to mobilise. Of the four patients using wheel-
chairs to mobilise, two were ambulatory with bilateral
assistance for short distances, and two were essentially con-
ﬁned to the wheelchair, requiring assistance to transfer. Of
the 88 patients who had their fracture risk calculated, 37
Table 1 Data used in the calculation of fracture risk for each of the three risk scoring algorithms
FRAX QFracture MS-specific calculator
Age Age Age
Sex Sex Sex
Weight; height; BMI Weight; height; BMI BMI
Previous fracture Previous fragility fracture Previous fracture (any fracture only)
Parental hip fracture Parental osteoporosis or hip fracture
Current smoking Current or previous smoking, number of
cigarettes smoked
Current smoking
Glucocorticoid exposure Regular glucocorticoid exposure Use of oral/intravenous glucocorticoids in the
prior 6 months
Rheumatoid arthritis Rheumatoid arthritis or SLE
Secondary osteoporosis
Alcohol >3 units/day Alcohol number of units/day
Femoral neck DXA (if
available)
Ethnicity
Diabetes
Nursing/care home residence
Falls History of a fall 3 months–1 year prior
Dementia
Cancer
Asthma/COPD
Heart attack, angina, stroke, TIA
Chronic liver disease
Chronic kidney disease
Parkinson’s disease
Malabsorption including Crohn’s disease
Endocrine problems including thyroid
dysfunction
Epilepsy/anticonvulsant exposure Use of anticonvulsants 6 months prior (any
fracture risk only)
Antidepressants Use of antidepressants in the prior 6 months
Oestrogen-only HRT
History of fatigue in the prior 6 months (hip
fracture only)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DXA, dual x-ray absorptiometry; HRT, hormone replacement therapy;
SLE, systemic lupus erythematosus; TIA, transient ischaemic attack.
Glucocorticoid exposure: defined currently as exposure to oral glucocorticoids or previous exposure to oral glucocorticoids for more than
3 months at a dose of prednisolone of 5 mg daily or more (or equivalent doses of other glucocorticoids).
Secondary osteoporosis: defined as a disorder strongly associated with osteoporosis. These include type I (insulin dependent) diabetes,
osteogenesis imperfecta in adults, untreated long-standing hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic
malnutrition or malabsorption and chronic liver disease.
Dobson R, Leddy SG, Gangadharan S, et al. BMJ Open 2013;3:e002508. doi:10.1136/bmjopen-2012-002508 3
Assessing fracture risk in MS
(42%) used a walking aid; of these, 6 (7%) required bilat-
eral assistance, 2 (2%) used a wheelchair for longer dis-
tances only and 1 (1%) was essentially wheelchair bound.
Of the 100 patients, 49 reported falling in the preceding
6 months; of the 88 patients with full fracture risk data, 48
(54.5%) reported a history of falls. Twenty two (52%)
patients using a walking aid reported falls in the preceding
6 months compared to 28% of those who did not require
a walking aid. No patients had a history of a prior fracture
meeting the deﬁnition of a fragility fracture.14
Fracture risk
Ten-year risk of any fracture
Mean 10-year fracture risk was 4.7% assessed by FRAX (SD
3.20, range 2.3–19.0), 2.3% assessed by QFracture (SD
2.14, range 0.4–13.0) and 7.6% using the MS-speciﬁc cal-
culator (SD 5.05, range 2.0–25.0) (table 3). Despite
efforts, it was not possible to normalise the distribution for
any of the fracture risk scores. There was an overall signiﬁ-
cant difference between the scores generated by the three
algorithms (p<0.001; Friedman test), which was preserved
on pairwise testing (p<0.001 for all comparisons,
Wilcoxon signed rank test) (table 3 and ﬁgure 1A).
Bland-Altman plots revealed a reasonable agreement
between FRAX and QFracture at lower fracture risk scores,
but for those patients with a higher fracture risk, a system-
atic error was apparent with QFracture consistently giving
lower risk estimates than FRAX (mean difference 2.68)
(ﬁgure 2A). When FRAX and the MS-speciﬁc risk score
were compared, the agreement was poor, with FRAX con-
sistently lower than the MS-speciﬁc score (mean difference
2.97) (ﬁgure 2B). The same could be seen when
QFracture and the MS-speciﬁc risk score were compared
(mean difference 5.60; data not shown).
Given that 50 of the patients were younger than 40, the
minimum age used in the FRAX calculation, the results
obtained for the 38 patients aged 40 or over were com-
pared in a sub-group analysis. This revealed similar results
to those obtained when all patients were included
(ﬁgure 1B). The highly signiﬁcant difference in the results
obtained by all three fracture risk scores remained
(p<0.001 for all comparisons, Wilcoxon signed rank test).
The κ coefﬁcient was calculated for the agreement
between rank quintiles for pairs of fracture risk scores. All
comparisons generated a low κ value, indicative of poor
agreement between rank quintile assignments (FRAX vs
QFracture: κ 0.065, 95% CI −0.05 to 0.181, weighted κ
0.133; FRAX vs MS-speciﬁc score: κ 0.084, 95% CI −0.029
to 0.197, weighted κ 0.225, QFracture vs MS-speciﬁc score:
κ 0.114 95%, CI −0.006 to 0.235, weighted κ 0.057).
The number of patients who met the predetermined cri-
teria for DXA imaging and treatment is given in table 3.
There was a signiﬁcant difference between all three
groups for both DXA imaging (p<0.0001 for all compari-
sons) and treatment (p=0.03 when comparing FRAX and
QFracture, otherwise p<0.0001). Of the six patients who
had previously undergone DXA imaging, three met the
criteria for imaging using either the FRAX or MS-speciﬁc
risk score, but none met the fracture risk cut-off for
imaging using the QFracture algorithm. Of the six patients
who had undergone DXA imaging, four were on no treat-
ment, one was taking calcium supplementation and one
hormone replacement therapy. None of the patients had
been diagnosed with osteoporosis.
Ten-year risk of hip fracture
Mean 10-year hip fracture risk was 0.7% as assessed by
FRAX (SD 0.95, range 0.1–5.6), 0.2% assessed by
QFracture (SD 0.55, range 0.0–4.8) and 3.4% using the
MS-speciﬁc calculator (SD 7.78, range 0.0–55.0) (table
3). Again, it was not possible to normalise the distribu-
tion for any of the fracture risk scores. There was an
Table 2 Patient details
Characteristic Patients (n=88)
Age (mean, range) 37.5 y (22–56)
Female (n, %) 55 (62.5%)
Disease duration (mean, range) 7.96 y (0–30)
Disease-modifying therapy 76/88 (86.4%) Receiving disease-modifying therapy
5/88 (5.7%) Glatiramer acetate (Copaxone)
15/88 (17.0%) Interferon β preparations
56/88 (63.6%) Natalizumab (Tysabri)
Ambulatory assistance required 37 (42%) Used a walking aid
28 (32%) Unilateral assistance, ie, single stick
6 (7%) Bilateral assistance
3 (3%) Wheelchair
BMI (mean, range) 24.4 (15.5–46.1)
BMI <20 (n, %) 15 (17%)
Current smoking (n, %) 28 (31.8%)
History of falls (n, %) 48 (54.5%)
Previous fragility fracture 0 (0%)
Previous DXA imaging 6 (6.8%)
BMI, body mass index; DXA, dual x-ray absorptiometry.
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overall signiﬁcant difference between the scores gener-
ated by the three algorithms (p<0.001; Friedman test),
which was preserved on pairwise testing (p=0.004 for
comparison of FRAX and MS-speciﬁc risk calculator,
p<0.001 for other comparisons, Wilcoxon signed rank
test) (table 3 and ﬁgure 3A). Again, when only those
aged 40 or over were analysed separately, the signiﬁcant
difference in the 10-year fracture risks generated by
the fracture risk calculators differed signiﬁcantly
(ﬁgure 3B). Agreement between rank quintiles was poor
(FRAX vs QFracture: κ 0.022, 95% CI −0.108 to 0.152,
weighted κ 0.033; FRAX vs MS-speciﬁc score: κ 0.016,
95% CI −0.096 to 0.129, weighted κ 0.107, QFracture vs
MS-speciﬁc score: κ 0.165 95% CI 0.035 to 0.295,
weighted κ 0.235).T
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Figure 1 (A) Combined scatter and box-and-whisker plot
demonstrating a 10-year any fracture risk generated by each
of the three risk scoring algorithms. The box represents the
25th–75th centile bisected by the median, with the whiskers
the range. (B) 10-year any fracture risks generated by each of
the three risk scoring algorithms for those patients aged 40 or
over only. The box represents the 25th–75th centile bisected
by the median, with the whiskers the range.
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The comparison of scores generated similar
Bland-Altman plots to those seen when examining the
data for overall fracture risk (data not shown). There was
no signiﬁcant difference between FRAX and QFracture in
the number of patients who met the predetermined treat-
ment threshold; however, both differed signiﬁcantly from
the MS-speciﬁc fracture risk calculator (p<0.0001 for both
comparisons).
DISCUSSION
From the results presented above, it can be seen that
the agreement between the three fracture risk calcula-
tors is poor in this population, both in absolute terms
and when examining rank quintiles. There have been
previous attempts to compare the results obtained by
FRAX and QFracture,15 16 and these have highlighted
similar issues.17 When the authors of the MS-speciﬁc
score compared the scores generated by their model to
those generated by the FRAX algorithm, they found that
FRAX appeared to signiﬁcantly underestimate fracture
risk for patients with MS, especially with regard to hip
fracture.6
One failure of the FRAX algorithm is that it does not
allow the calculation of accurate risk for those aged <40; as
the majority of our patients were aged between 20 and 40,
this could represent a source of error. However, the ﬁnd-
ings did not differ signiﬁcantly when only those patients
aged 40 or over were included. A signiﬁcant limitation of
this study was the relatively small sample size (n=88),
which was further reduced in the subgroup analysis of
those patients aged 40 or over (n=38). This must be borne
in mind when interpreting the results; however, the magni-
tude of the differences cannot be ignored.
The FRAX algorithm has been criticised previously for
not incorporating factors such as falls15; while this is a
signiﬁcant omission, it would be expected that this
would lead to an underestimation of risk when using
this calculator. However, the QFracture algorithm, which
does incorporate falls into the calculation, gave consist-
ently lower fracture risk scores than the FRAX calculator.
This may be due to a more accurate estimate of age-
speciﬁc risk, as the QFracture allows the imputation of
age from age 30. However, despite including Parkinson’s
Figure 3 (A) 10-year hip fracture risks generated by each of
the three risk scoring algorithms for all patients. The box
represents the 25th–75th centile bisected by the median, with
the whiskers the range. (B) 10-year hip fracture risks
generated by each of the three risk scoring algorithms for
those patients aged 40 or over only. The box represents the
25th–75th centile bisected by the median, with the whiskers
the range.
Figure 2 (A) Bland-Altman plot comparing FRAX
and QFracture scores for 10-year risk of any fracture.
(B) Bland-Altman plot comparing FRAX and MS-specific
scores for 10-year risk of any fracture.
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disease as a factor, the QFracture calculator does not
include MS.
The MS-speciﬁc calculator appeared to be consistently
overestimating fracture risk. While one might imagine
that this would be the most accurate of the risk calcula-
tors, the number of patients judged to be over either the
investigation or treatment threshold was far higher than
expected. This risk calculator was generated from the
UK General Practice (GP) database. It incorporates a
number of factors into the risk calculator that are not
captured by other risk calculators, such as recent steroid
use (as a surrogate for relapses) and fatigue (hip frac-
ture risk calculation only). However, it has been shown
previously that coding is of variable accuracy in the GP
database.18 As most of the short courses of intravenous
steroids are given in secondary care, it is not inconceiv-
able that these would not be captured accurately.
Additionally, while more than half of the patients with
MS report fatigue when directly questioned,19 it is quite
likely that only those with the very highest levels of
fatigue have this recorded by their GPs.
The lack of agreement between the fracture risk calcu-
lation tools is likely to be, at least in part, a result of the
ways in which they have been developed. FRAX was
developed using fracture incidence rates in the UK
general population, while the other two calculators have
been generated using the UK GP database. Differences
in fracture reporting and recording, together with differ-
ences in the recording of fracture risk factors between
these databases, are likely to contribute to the differ-
ences between the results generated in the population
studied. This study highlights the fact that the results
generated by one fracture risk scoring tool cannot be
substituted for those generated by another, and consist-
ent use of a single tool within a population is required
to stratify risk in that population. Similarly, the thresh-
olds for further investigation or treatment are likely to
vary between the risk scoring tools. The NOGG guid-
ance9 has been developed with reference to the FRAX
tool, and so should be used in conjunction with this.
To date, there are no papers examining the primary
prevention of osteoporosis or osteoporotic fractures in
MS. There is also a need to assess the effect of MS
disease-modifying treatments on fracture risk. Whether
MS disease-modifying treatments have any effect on
BMD outside of a general beneﬁcial effect on bone
health through the maintenance of weight-bearing
mobility remains controversial. Theoretically, interferon-
beta preparations should protect against bone mineral
loss in MS through induction of the tumour necrosis
factor-related apoptosis-inducing ligand (TRAIL).20
There is a single paper demonstrating that people with
MS treated with interferon-beta had z-scores signiﬁcantly
greater than zero,21 but there was no control group in
this study, meaning that it is impossible to draw any ﬁrm
conclusions regarding this. There remains much work to
be done with regard to assessing fracture risk in the MS
population, who are at a high risk of fracture and
associated complications. While reducing fracture risk
should be a priority to all clinicians dealing with chronic
conditions associated with an increased risk of fracture,
there must be consistency in the way in which fracture
risk is calculated. A prospective study on the MS popula-
tion, encompassing both fracture risk calculation and
bone densitometry estimation using DXA, is urgently
needed in order that we can determine the best way to
assess the risk, and act to prevent fractures.
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